ConvaTec Group

ConvaTec Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of ConvaTec Group (CTEC.L) as of Nov 12, 2026 is 195.44 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 143.88 % — a change of 35.83% (higher).

FCF Conversion

195.44 %

YoY

35.83%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of ConvaTec Group is 2025 195.44 % . FCF Conversion Rate (FCF/EBITDA) of ConvaTec Group was 2024 143.88 % . It decreases by 35.83% higher compared to the previous year.

The ConvaTec Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
126.31 USD
Jan 1, 2019
3,473.47 USD
Jan 1, 2020
278.49 USD
Jan 1, 2021
180.10 USD
Jan 1, 2022
218.60 USD
Jan 1, 2023
182.81 USD
Jan 1, 2024
143.88 USD
Jan 1, 2025
195.44 USD
The ConvaTec Group FCF Conversion history
YEARFCF ConversionYoY
195.44 %+35.83%
143.88 %-21.29%
182.81 %-16.37%
218.60 %+21.38%
180.10 %-35.33%
278.49 %-91.98%
3,473.47 %+2,649.99%
126.31 %-10.64%
141.35 %-3,512.62%
-4.14 %-93.92%
-68.09 %+90.15%
-35.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ConvaTec Group Stock analysis

What does ConvaTec Group do? ConvaTec Group is a global leading company specialized in the development and manufacturing of medical products and technologies for chronic diseases and wounds. The company was founded in the UK in 1978 and has since established a strong presence in over 100 markets worldwide. Over time, ConvaTec has become a significant leader in the healthcare industry. The company was originally founded by doctors to develop better therapies for patients with chronic diseases and wounds. It started with the development of skincare products for individuals with impaired skin barrier, such as patients with stoma and incontinence. Today, ConvaTec offers a variety of products and therapies for chronic diseases and wounds. ConvaTec operates its business in multiple product segments, each offering unique products and services. These segments include Advanced Wound Care, Infusion Devices, Stoma Care, and Continence and Critical Care. As a company, ConvaTec places a strong emphasis on innovation and research to continuously improve products and meet new medical needs. Collaborating closely with physicians, nursing staff, and patients is also emphasized. ConvaTec offers a comprehensive product portfolio. Advanced Wound Care includes a wide range of wound care products, including hydrocolloid dressings, foam dressings, and other biological collagen products. Infusion Devices consist of pump systems and catheters for administering fluids, medications, and nutrients over an extended period. Stoma Care produces products that support patients with an artificial opening to continue their daily lives as normally as possible. Continence and Critical Care provide solutions for bladder and bowel management of patients in critical situations, such as intensive care units. ConvaTec has become a leading company in the field of medical products and technologies over the years, thanks to its innovative products and a consistent focus on meeting people's needs. Through the use of new technologies and a strong focus on user feedback, ConvaTec has contributed to improving the lives of patients worldwide. Output: ConvaTec Group is a global leading company specialized in the development and manufacturing of medical products and technologies for chronic diseases and wounds. ConvaTec Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ConvaTec Group stock

FCF Conversion Rate (FCF/EBITDA) of ConvaTec Group is 195.44 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of ConvaTec Group changed from 143.88 % to 195.44 %, representing a 35.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) ConvaTec Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s ConvaTec Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ConvaTec Group

All Key Metrics — ConvaTec Group